small molecule

SUPPRELIN LA

HISTRELIN ACETATE

Loss of exclusivityJune 2026latest FDA-listed patent expiry
CompanyENDO OPERATIONS LTD

Drug detail

Brand nameSUPPRELIN LA
Active ingredientHISTRELIN ACETATE
Strength50MG
Dosage formIMPLANT
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalMay 2007
Marketing statusRX

Listed patents

PatentExpiresType
8062652June 2026use U-1197

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SUPPRELIN LA patent cliff — loss of exclusivity June 2026 | CliffBio